Q-Line Biotech Ltd. (QBL) is engaged within the enterprise of creating, manufacturing and advertising of numerous vary of reagents (together with kits and POC units) & consumables and manufacturing, importing, distribution/provide of diagnostic gear for various diagnostic healthcare wants. The corporate provides diagnostic gear and IVD merchandise for various diagnostic healthcare wants since 2013 straight or by way of its distributor/s majorly to diagnostic service suppliers, hospitals and medical faculties.
The corporate has established its manufacturers over a interval of 12 years by way of its expertise, R & D, manufacturing capabilities and high quality assurance. The core segments of operations of the Firm in IVD Business embody Medical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Gadgets & Rapids).
QBL’s key manufacturing segments embody indigenous manufacturing of reagents together with Medical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Gadgets & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology gear’s & units. Additional throughout the Covid-19 pandemic, the corporate diversified its focus and with the technical collaboration of third-party institutes and thru its personal R&D crew developed a variety of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits and so on.
It’s analysis pushed firm engaged in creating and manufacturing a variety of reagents formulations used throughout varied IVD and diagnostic wants. The corporate leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /merchandise. Additional, for its sure Class of Reagent & gear’s and units manufacturing enterprise, the corporate has entered into technical collaboration with sure worldwide corporations. Underneath the settlement phrases, it undertakes the manufacturing of those Reagent and gear’s and units as per the technical collaboration and specs offered by the companions or corporations.
With the assistance of those collaborations the gear and units adhere to strict high quality management, worldwide requirements and certifications. As of March 31, 2026, the corporate employed 19 personnel at R&D laboratories, which constituted 5.25% of its whole everlasting worker energy. As of March 31, 2026, it had 362 staff on its payroll and extra 223 contract staff in varied departments.
Concern Particulars / Capital Historical past
The corporate is popping out with its maiden e-book constructing route IPO of 6253200 fairness shares of Rs. 10 every to mobilize Rs. 214.48 cr. on the higher cap. The corporate has introduced a worth band of Rs. 326 – Rs. 343 per share. The minimal software to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on Could 21, 2026, and can shut on Could 25, 2026. The IPO represent 26.81% of the post-IPO paid-up capital of the corporate. The shares can be listed on NSE SME Emerge. From the online proceeds of the IPO, it’s going to make the most of Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for compensation/prepayment of sure borrowings, and the remainder for basic company functions.
The corporate raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in Could 2026, at Rs. 343 per share.
The IPO is collectively lead managed by Hem Securities Ltd., and Share India Capital Companies Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the difficulty. HEM group’s Hem Finlease Pvt. Ltd., is the market maker in addition to a syndicate member.
The corporate has issued preliminary fairness capital at par worth. It raised additional fairness shares within the worth vary of Rs. 125 – Rs. 417 between March 2019 and Could 2026. It has additionally issued bonus shares within the ratio of two for 1 in March 2016, and 9 for 1 in August 2025. The typical price of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.
Publish-IPO, firm’s present paid-up fairness capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based mostly on the higher band of the IPO pricing, the corporate is in search of a market cap of Rs. 800.16 cr.
IPO Lead Managers & Registrar
On the monetary efficiency entrance, for the final three fiscals, the corporate has (on a consolidated foundation) posted whole revenue/ internet revenue, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a internet revenue of Rs. 38.69 cr. on a complete revenue of Rs. 236.50 cr. Although it posted progress in its high strains for the reported durations, its backside line posted inconsistency. For FY25, it posted decrease internet revenue of Rs. 28.13 cr., and for 9M-FY26, although the highest line is Rs, 236.50 cr. it posted bumper revenue of Rs. 38.69 cr. in a pre-IPO interval, that not solely increase eyebrows, but additionally concern over its sustainability going ahead. Regardless of larger different revenue for FY25, it marked decrease internet following extra-ordinary merchandise of Rs. 16.97 cr. Its contingent legal responsibility stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its total borrowings of Rs. 242.57 cr. as of December 31, 2025, increase concern.
For the final two fiscals, the corporate has reported a mean EPS of Rs. 25.00, and a mean RoNW of 23.17%. The difficulty is priced at a P/BV of two.44 based mostly on its NAV of Rs. 140.81 per share as of December 31, 2025, however its post-IPO NAV information is lacking from the provide paperwork.
If we attribute FY26 tremendous earnings to its post-IPO totally diluted paid-up fairness capital, then the asking worth is at a P/E of 15.51, and based mostly on FY25 earnings, the P/E stands at 28.44. The difficulty seems totally priced, based mostly on its bumper earnings for 9M-FY26, which will not be sustained.
For the reported durations, the corporate has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of twenty-two.14%, 19.25%, 17.66%, 13.32%, respectively, for referred durations.
All quantities in Indian Rupees crores
The corporate has not paid any dividends for the reported durations of the provide doc. It can undertake a prudent dividend coverage, based mostly on its monetary efficiency and future prospects.
Comparability with Listed Friends – for Fiscal 2025
As per the provide doc, the corporate has no listed friends to check with.
Service provider Banker’s Observe Report
The 2 service provider bankers related to this concern have dealt with 79 points previously three years, out of which 8 points closed beneath the difficulty worth on itemizing date.
Conclusion – Apply for medium to long run
QBL is engaged within the enterprise of creating, manufacturing and advertising of numerous vary of reagents and consumables. It posted progress in its high strains for the reported durations, however suffered a setback for FY25 in backside line following accounting changes. As the corporate has no listed friends, it’s attempting to extract fancy worth for its IPO. Based mostly on its total monetary information, the difficulty seems totally priced. Nicely-informed buyers could park reasonable funds for long run.
Dilip Davda is a veteran monetary journalist related to the Indian inventory market since 1978. He has been contributing to print and digital media on capital markets, insurance coverage, and finance since 1985.
He’s widely known for reviewing public points and non-convertible debentures (NCDs) within the major market. Drawing on over three a long time of market expertise and shut interplay with service provider bankers, his evaluations give attention to detailed elementary and monetary evaluation of corporations, with a particular emphasis on SME public points.
Disclaimer: The knowledge offered herein is solely for instructional and informational functions and doesn’t represent a suggestion, solicitation, or advice to purchase or promote any securities. Readers are suggested to seek the advice of a certified monetary advisor earlier than making any funding selections. Investments within the securities market are topic to market dangers. The writer doesn’t intend to spend money on the securities mentioned.
